Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.

Antimicrobial Agents and Chemotherapy
J Chan, B J Luft

Abstract

Roxithromycin (RU 28965), an ether oxime derivative of erythromycin, protected mice against a lethal infection with the virulent RH strain of Toxoplasma gondii. Therapy begun 24 h before, 2 h after, and 24 h after infection with 2 X 10(3) tachyzoites protected 90, 80, and 50% of the mice, compared with 0% of untreated controls (P less than 0.05 to 0.001). Toxoplasma was isolated in less than 20% of surviving roxithromycin-treated mice.

References

Feb 1, 1976·Antimicrobial Agents and Chemotherapy·J S Remington
Mar 1, 1954·American Journal of Proctology
Jun 1, 1959·A.M.A. Archives of Ophthalmology·H E KAUFMAN, L A CALDWELL
Jul 1, 1960·Archives of Ophthalmology·H E KAUFMAN, P H GEISLER

❮ Previous
Next ❯

Citations

Jan 1, 1992·Journal of Clinical Pharmacology·S ChuJ C Cavanaugh
Feb 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N ClumeckS De Wit
Jun 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F G AraujoJ S Remington
Aug 1, 1987·European Journal of Clinical Microbiology·B J Luft
Feb 1, 1987·European Journal of Clinical Microbiology·R N Jones, A L Barry
Jul 1, 1987·Antimicrobial Agents and Chemotherapy·H R Chang, J C Pechere
May 1, 1988·Antimicrobial Agents and Chemotherapy·F G AraujoJ S Remington
Sep 1, 1989·Antimicrobial Agents and Chemotherapy·H A Kirst, G D Sides
May 1, 1990·Antimicrobial Agents and Chemotherapy·H R ChangJ C Pechère
May 1, 1991·Antimicrobial Agents and Chemotherapy·S ChamberlandW L Current
Jul 1, 1994·Antimicrobial Agents and Chemotherapy·J C SchwabK A Joiner
May 24, 2014·Experimental Parasitology·M R GaafarTh I Shalaby
Jan 1, 1988·Scandinavian Journal of Infectious Diseases·T U Westblom, R B Belshe
Oct 9, 2015·Parasitology Research·Rasha F MadySamar Elachy
Apr 24, 2010·Médecine et maladies infectieuses·D SimanaityteL Legout
Jun 2, 1988·The New England Journal of Medicine·A E GlattS H Landesman
Jan 1, 1996·International Journal of STD & AIDS·H R Chang
Sep 24, 2015·Antimicrobial Agents and Chemotherapy·Andrew J NevillePaul H Davis
Mar 2, 2018·Journal of Parasitic Diseases : Official Organ of the Indian Society for Parasitology·Samia E EtewaMahmoud A El-Shafey

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.